| Autor: |
Molz P; Laboratory of Experimental Nutrition, University of Santa Cruz do Sul, Santa Cruz do Sul, RS, Brazil. patricia.molz@gmail.com.; Graduate Program in Health Promotion, University of Santa Cruz do Sul, Santa Cruz do Sul, RS, Brazil. patricia.molz@gmail.com.; Graduate Program in Health Promotion, University of Santa Cruz do Sul, Av. Independência, 2293, Santa Cruz do Sul, RS, 96815-900, Brazil. patricia.molz@gmail.com., Molz WA; Medicine Course, Department of Life Sciences, University of Santa Cruz do Sul, Santa Cruz do Sul, RS, Brazil., Dallemole DR; Laboratory of Histology and Pathology, University of Santa Cruz do Sul, Santa Cruz do Sul, RS, Brazil., Weber AF; Laboratory of Histology and Pathology, University of Santa Cruz do Sul, Santa Cruz do Sul, RS, Brazil., Salvador M; Laboratory of Oxidative Stress and Antioxidants, University of Caxias do Sul, Caxias do Sul, RS, Brazil., Prá D; Laboratory of Experimental Nutrition, University of Santa Cruz do Sul, Santa Cruz do Sul, RS, Brazil., Franke SIR; Laboratory of Experimental Nutrition, University of Santa Cruz do Sul, Santa Cruz do Sul, RS, Brazil.; Graduate Program in Health Promotion, University of Santa Cruz do Sul, Santa Cruz do Sul, RS, Brazil. |
| Abstrakt: |
Chromium (III) (Cr(III)) effect on improving glucose, body mass loss, and genomic stability has been extensively studied in models of type 2 diabetes. However, there is a lack of studies evaluating its effect on prediabetes. Thus, this study evaluates the effects of Cr(III) as dietetic supplementation on glucose metabolism, obesity, and genomic stability on prediabetic rat model using high-invert sugar. Male Wistar rats were divided randomly into four treatment groups: (1) control, receiving standard diet (control); (2) prediabetic (PD), receiving a 32% of invert sugar; (3) Cr(III), receiving chromium (III) chloride (CrCl 3 •6H 2 O) (58.4 mg/L); and (4) Cr(III) + PD, receiving CrCl 3 •6H 2 O in combination with high-invert sugar. Cr(III) supplementation significantly reduced blood glucose (123.00 ± 8.29 mg/dL vs. 115.30 ± 9.31 mg/dL, p = 0.015) and partially reduced area under the 120-min blood glucose response curve (AUC) in PD rats (p = 0.227). Moreover, Cr(III) attenuated weight gain (187.29 ± 38.56 g vs. 167.22 ± 29.30 g, p = 0.004), significantly reducing body mass index (0.68 ± 0.04 g/cm 2 vs. 0.63 ± 0.04 g/cm 2 , p < 0.001), Lee index (0.30 ± 0.01 vs. 0.28 ± 0.01, p < 0.001), and peritoneal fat (p < 0.001). Regarding genomic stability, high-invert sugar, Cr(III), or the combination of both did not produce changes in oxidative stress, DNA damage in pancreas, or cytotoxicity markers. These data suggest that Cr(III) supplementation improved partially glucose metabolism and reduced obesity in rat model PD due to high-invert sugar without influence in genomic stability. |
Full text from SpringerLink